NCT04701216

A Trial of SHR8735 in Healthy Subjects

A Phase 1 Open-Label Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of SHR8735 in Healthy Chinese and Caucasian Subjects

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 48 (actual)
• Sponsor: Atridia Pty Ltd. · Industry
• Sex: All
• Age: 18 Years – 55 Years
• Healthy volunteers: Accepted

Summary

This is a phase 1 open-label study.

Detailed description

This is a phase 1 open-label study. The objective of this study is to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of oral administered SHR8735 in healthy subjects

Conditions

• Healthy Volunteers

Interventions

Type	Name	Description
DRUG	SHR8735	SHR8735 is an thrombopoietin receptor agonist to promote platelet production.

Timeline

• Start date: 2021-02-11
• Primary completion: 2021-07-15
• Completion: 2021-07-15
• First posted: 2021-01-08
• Last updated: 2021-11-09

Locations

1 site across 1 country: Australia